We thank De Pascalis and Cianciolo[@bib1] for their comment on additional off-target effects of SGLT-2 inhibitors on sodium-hydrogen exchangers (NHEs). However, the purpose of our report was to elucidate whether tubuloglomerular feedback is altered in a natural model mimicking long-term SGLT-2 inhibitor therapy, which was not the case.

A variety of mechanisms that might explain the cardiorenal-protective effects of SGLT-2 inhibitors have been proposed. Concerning NHEs, it is interesting that NHE-3 activity, which colocalizes with SGLT-2, is stimulated at low but inhibited at high glucose concentrations or after SGLT inhibition by phlorizin in male Wistar rats.[@bib2] However, these experimental data still need to be evaluated further for their significance in the human setting. Of note, the same is true for other potential cardiorenal-protective mechanisms such as, among others, reduction in blood pressure, improvement of salt sensitivity/erythropoiesis, reduced oxidative stress, and switching glucose to ketone bodies/fatty acid metabolism in the myocardium.[@bib3] From this point of view, we naturally agree with De Pascalis and Cianciolo that more data are needed on all proposed mechanisms to fully explain the beneficial effects of SLGT-2 inhibitors on kidney and cardiovascular outcomes.
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